Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Rinsch

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Transplantation|March 10, 2001
Inducing host acceptance to encapsulated xenogeneic myoblastsC Rinsch, G Peduto, B L Schneider, et al.
Human Gene Therapy|February 7, 1998
A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tensionC Rinsch, E Régulier, N Déglon, et al.
Transplantation|August 5, 2000
Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppressionG Peduto, C Rinsch, B L Schneider, et al.
Gene Therapy|August 24, 1999
Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretionP Dupraz, C Rinsch, W F Pralong, et al.
Gene Therapy|April 25, 2001
Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemiaC Rinsch, P Quinodoz, B Pittet, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Transplantation|March 10, 2001
Inducing host acceptance to encapsulated xenogeneic myoblastsC Rinsch, G Peduto, B L Schneider, et al.
Human Gene Therapy|February 7, 1998
A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tensionC Rinsch, E Régulier, N Déglon, et al.
Transplantation|August 5, 2000
Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppressionG Peduto, C Rinsch, B L Schneider, et al.
Gene Therapy|August 24, 1999
Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretionP Dupraz, C Rinsch, W F Pralong, et al.
Gene Therapy|April 25, 2001
Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemiaC Rinsch, P Quinodoz, B Pittet, et al.
Pageof 1